Familial Myeloproliferative Disorders

Sponsor

Icahn School of Medicine at Mount Sinai (Other)

Overall Status

Completed

CT.gov ID

NCT00666289

Collaborator

Myeloproliferative Disorders-Research Consortium (Other), National Cancer Institute (NCI) (NIH)

Enrollment

Locations

87.6

Duration (Months)

2.8

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Myeloproliferative disorders occur in families, thus giving rise to the theory that it is a genetic disease that may be caused by an abnormal gene in the DNA that can be passed from one generation of family members to another. DNA can be gathered from family members through blood samples and the investigators will investigate (through DNA testing) to see if there are abnormal genes that may be responsible for causing the MPDs. Understanding which genes are responsible for causing MPDs can help develop ways to identify people who may be at risk for developing an MPD, allow for the development of better treatments, possibly a cure, or even prevent the development of MPDs.

Condition or Disease	Intervention/Treatment	Phase
Polycythemia Vera Essential Thrombocythemia Idiopathic Myelofibrosis

Study Design

Study Type:

Observational

Actual Enrollment :

17 participants

Observational Model:

Family-Based

Time Perspective:

Other

Official Title:

Molecular Biology of Familial Myeloproliferative Disorders

Study Start Date :

Mar 1, 2008

Actual Primary Completion Date :

Jan 20, 2015

Actual Study Completion Date :

Jun 20, 2015

Outcome Measures

Primary Outcome Measures

To determine a linkage from the DNA analyzed to find a gene that will allow for genetic evaluation of families with MPDs. [3 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

7 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Families with 2 or more members diagnosed with polycythemia vera (PV), essential thrombocythemia (ET), PV and ET related myelofibrosis (PV-MF and ET-MF), idiopathic myelofibrosis (IM) or chronic myelogenous leukemia (CML).
Healthy family members of subjects diagnosed with a myeloproliferative neoplasm (MPN).
Participating subjects must be 7 years of age or older
A written assent, parental permission or consent must be obtained prior to any study procedures being performed.

Exclusion Criteria:

Subjects who have a known acquired cause of polycythemia (increased hemoglobin/hematocrit), such as people living in high altitudes (in excess of 14,000 feet), subjects with heart disease, left to right heart shunt, severe hypoxia, cyanotic congenital heart disease, or severe pulmonary disease, will be excluded from this study, secondary forms of thrombocytosis and secondary forms of myelofibrosis.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Georgetown University	Washington, D.C.	District of Columbia	United States	20057
2	University of Illinois at Chicago	Chicago	Illinois	United States	60612
3	Mount Sinai School of Medicine	New York	New York	United States	10029
4	Weill Cornell	New York	New York	United States	10065
5	University of Utah	Salt Lake City	Utah	United States	84102
6	University of Florence	Florence		Italy